When your trials rely on an investigational product (IP), your study timeline, budget, and overall success are closely tied to having the right product available at the right time and site. Once randomization is added in, sponsors can struggle to maintain an increasingly complex supply chain.
Randomization & Trial Supply Management (RTSM) aims to alleviate these pain points by solving high-risk and high-cost trial needs through an intelligent approach to operational management. Due to the inherently changing nature of randomized trials, both adaptive designs and master protocols require a highly sophisticated RTSM solution to swiftly and efficiently introduce mid-study protocol adjustments.
An effective RTSM can help sites, sponsors, and study managers avoid common pitfalls associated with a complex supply chain, including:
When a master supply strategy is created and executed through a robust, integrated RTSM solution, it can become a powerful tool to achieve operational efficiency. It can also help your clinical teams detect an IP’s effectiveness with better accuracy and gain a better understanding of the dose-response relationship.
But in an era of increased regulations and growing complexity, sponsors need to integrate RTSM throughout the entire IP development lifecycle—from initial production through final IP destruction—to realize its full potential. We will break down best practices sponsors can take to incorporate RTSM into their study operations.
A lot can go wrong in your attempts to deliver products to hundreds of remote sites and dispersed teams around the world. Much like a game of dominoes, any disruption to the supply chain has a ripple effect that can result in lengthy and costly delays to sponsors.
Getting RTSM right means early involvement of logistics experts in the clinical trial planning process to create a unified supply strategy. In tandem with drafting the study protocol, a master supply strategy should be created that integrates with your RTSM system from initial production, to packaging and labeling, through to final disposal.
No two trials are the same and each unique site requires different logistical considerations. A master supply strategy takes an intelligent and flexible approach to supply management so teams don’t need to develop new, trial-specific protocols as they scale and expand.
When developing your strategy, sponsors should consider:
There are many considerations that go into planning your master supply strategy; but if executed in tandem with building out your RTSM system, it can help sponsors achieve operational synergy through one single solution.
A Tufts Center for the Study of Drug Development study found that despite the growing number of clinical data sources, only one-third of sponsors currently have a data strategy in place. Even worse, it’s estimated that 15 – 30% of data collected during clinical trials were never used in new drug applications. This has contributed to longer database lock cycle times that cause downstream delays in drug and IP development.
In addition to being a helpful tool for supply chain management, RTSM can be a powerful clinical data source when leveraged correctly. A clinical trial supply may rely on multiple systems—one to control randomization and dispensation, another to track shipment and environmental factors, and a separate EDC to funnel clinical data into. Without a unified integration between these systems, data transfer delays and reconciliation requirements can occur between dispersed sites and teams.
A delay in data exchange could prevent a clinical team from determining if an IP is approved for dispensation or confirm if a kit’s temperature has been properly maintained in transit. And each day a drug is delayed could end up costing a sponsor between $600,000 to $8 million. By seeing your RTSM as a critical source of clinical data, and integrating it with your eClinical suite, sponsors and study managers can enable live data exchanges and streamline their end-to-end operations.
When successfully integrated into a study’s supply operations, RTSM can help sponsors access:
Before finalizing your master supply strategy and executing it through your RTSM, sponsors should consider including comprehensive risk-based monitoring (RBM) assessment. The risk assessment scans for higher risk areas in your trial supply and randomization and lower risk areas that can be adapted or simplified. Sponsors should focus their risk assessment on maintaining IP quality, prioritizing patient safety, and ensuring data integrity and compliance.
Risk assessments should evaluate the impact, probability, and detectability measures for a myriad of categories including:
To decrease the cost of clinical trials and increase patient adherence, sponsors should establish an ongoing risk-based monitoring plan within their RTSM. Monitoring continues to plague sponsors, driving up 25-30% of most trial costs. But risk-based monitoring is helping sponsors identify risks proactively, resulting in fewer risks in later-stage development that result in costly delays. With proper risk-based monitoring in place, sponsors can mitigate risks quickly, effectively maintaining the quality of a study and the safety of participants, while collecting high-quality, reliable data.
Incorporating RTSM into your operational management should be considered early in your planning process. Since trials are beholden to ensuring the trial materials arrive at the right site at the right time, it’s crucial to involve RTSM early.
Trial supply covers five major areas:
Without proper planning, a single disruption to the supply chain—from regulations and approvals to packaging and labeling, to temperature-controlled transport, and more specialized logistics—can significantly affect the budget and timeline of your trials.
Sponsors should consult with experts at every stage of their supply chain to ensure proper planning of the product lifecycle while identifying ways to reduce waste. Core supply decisions must be made about IP packaging, storage requirements and expiry, dosing instructions, visit schedules, resupply, and data management. Once decisions are set, the protocol can be tested and forecasted within your RTSM as part of your UAT process.
RTSMs help streamline trial supply management by providing visibility across the entire supply chain. Sponsors and study managers can achieve operational efficiency by relying on a single system to track inventory, ensure IP integrity, and minimize IP waste at their sites.
Once your supply strategy and data management strategies are finalized, be sure to consider your resupply strategy. RTSM connects your operational and clinical teams together on one single system so you have visibility over your inventory and randomization needs and can determine the best dispensing and resupply patterns for your trials. For many sponsors, this means feasibility for a lean, demand-driven fulfillment approach.
If the average rate of patient dropouts in clinical trials is 30%, it can be risky to give a patient a dedicated 10-week supply of an assigned treatment. If that patient withdraws from the study a few weeks in, the remaining supply is wasted and a new kit must be procured for the next patient assignment. Imagine how much IP can get wasted when 10-pack kits are accidentally damaged by the site, patient, or during delivery and storage. Instead of relying on bulk packaging or wasteful supply practices, RTSM is helping sponsors keep the right supply on-site and enable JIT trial supply.
Ways that RTSM supports demand-driven fulfillment:
Participation in randomized trials can be demanding, with patients reporting higher levels of psychological, physical, and financial burdens than traditional trials.7 The cost of patient recruitment and retention continues to demand sponsors, as well, costing an average of $41,117 per patient.
RTSM can help sponsors alleviate burdens associated with randomized clinical trials by establishing workflows that increase patient adherence and compliance.
Many RTSM solutions offer robust randomization or robust trial supply, but rarely both. The supply chain is deeply interconnected and randomization assignments directly impact your trial supply and vice versa. With an integrated solution of feature-rich randomization, trial supply, and EDC integration options, Medrio RTSM is the only solution equipped to support your end-to-end trial operations.
As Christine Hurley, COO at 4G Clinical, told Clinical Leader, “Over the years, it became apparent that supply management was just as critical as randomization and the combined action of them together elevates the function of this system. They are synergistic and need to co-exist.”
An efficient and cost-effective clinical trial supply chain requires the right systems and personnel are in place so that the right materials arrive at the right site at the right time. When all of the pieces come together, sponsors can realize a comprehensive, end-to-end solution that reduces costs and delays by streamlining supply logistics. These streamlined logistics help sponsors achieve operational efficiency while prioritizing patient safety and IP efficacy. Let us show you how Medrio RTSM can fully support your trial supply and randomization needs. Learn more about our robust solution or sign up for a demo today.
Download this whitepaper as a PDF.